Fablyns virkning i behandlingen af VVA blev undersøgt i to 12- ugers fase 3- studier med postmenopausale kvinder med moderate eller alvorlige tegn og symptomer på VVA, uafhængigt af osteoporose- status (889 patienter).
The efficacy of FABLYN in the treatment of VVA was investigated in two 12-week Phase 3 studies in postmenopausal women with moderate or severe signs and symptoms of VVA, regardless of osteoporosis status (involving 889 patients).